Printer Friendly

Research and Markets: Bladder Cancer -- High Recurrence Rates, Targeted Therapy to Stem the Flow?

DUBLIN, Ireland, March 30 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/reports/c14798 ) has announced the addition of Bladder Cancer -- High Recurrence Rates, Targeted Therapy to Stem the Flow? to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )

The incidence of bladder cancer is set to increase by 11% in the seven major pharmaceutical markets between 2004 and 2012. Current therapy yields notable response rates yet 80% of patients with superficial bladder cancer will relapse and there has been no advance in patient survival in the last decade. This brief examines current treatment issues and future directions in the bladder cancer market.
 Scope
 - Overview of disease including epidemiology, biology of bladder cancer,
 staging and prognostic variables
 - Current treatment options and clinical controversies
 - Key recommendations in the areas of greatest unmet need, including
 superficial and invasive bladder cancer
 - Profiles of key bladder cancer agents in late-stage development.
 Opinions from key bladder cancer specialists

 Highlights

 - There have been no improvements in patient survival over the last
 decade. In the setting of advanced disease combination regimens using
 Eli Lillys Gemzar are set to replace the current gold standard M-VAC,
 but this is likely to be due to an improved toxicity profile rather than
 increased efficacy.
 - We believe that the integration of new, targeted therapies in
 combination with chemotherapy may hold promise for preventing the
 progression to invasive bladder cancer. The most appropriate combination
 remains to be defined.
 - Optimal treatment will be dependant on an accurate assessment of disease
 prognosis. Thus the development of molecular markers which can predict
 patients at greatest risk of progression will be pivotal to improving
 patient survival.

 Reasons to Purchase

 - Identify future market opportunities by examining current unmet needs
 and how current therapy fails to improve survival for bladder cancer
 patients
 - Understand the epidemiology and current clinical treatments in bladder
 cancer
 - Plan new product development based on an understanding of physician
 expectation of molecular -- targeted therapy for bladder cancer




For more information visit http://www.researchandmarkets.com/reports/c14798
 Laura Wood
 Senior Manager
 Research and Markets
 press@researchandmarkets.com
 Fax: +353 1 4100 980



CONTACT: Laura Wood, Senior Manager, Research and Markets, press@researchandmarkets.com, Fax: +353-1-4100-980

Web site: http://www.researchandmarkets.com/reports/c14798
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 2005
Words:370
Previous Article:Research and Markets: In 4Q 2004 21 Million Broadband CPE Units Shipped, an Increase of 7% From 3Q 04.
Next Article:Research and Markets: State of the Market: A Demographic and Vertical Industry Profile of US Enterprises (1,000+ Employees).


Related Articles
Lack of Available Candidate Drugs Constraining the Bladder Cancer Drug Market; Eli Lilly's Gemzar Being Investigated as an Intravesical Therapy for...
Spectrum Pharmaceuticals Advances EOquin Program; * Has Initiated Pre-clinical Studies on EOquin in Combination with Radiotherapy;.
Cell Genesys Launches Phase 1 Trial of CG0070 in Recurrent Bladder Cancer.
FDA Approves First Gene-Based Test, UroVysion(TM), for Diagnosis of Patients Suspected of Having Bladder Cancer.
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial.
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial.
BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug.
The optimal management of T1 high-grade bladder cancer.
Update on the management of non-muscle invasive bladder cancer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters